Gupta N, et al. – Researchers in this study aimed to quantitatively characterize the benefit–risk profile of ixazomib in relapsed/refractory multiple myeloma (MM) in support of the approved dose and schedule. A favorable benefit–risk profile for weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28–day cycles, which was selected for the phase III TOURMALINE registration program was supported by this study.